文献速递神经肿瘤

成人胶质瘤中的循环肿瘤DNA:生物标志物性能的系统综述与Meta分析

Circulating Tumor DNA in Adults With Glioma: A Systematic Review and Meta-Analysis of Biomarker Performance.
PubMed 文献 · Neurosurgery · 2022-05-12

该系统综述与Meta分析评估成人胶质瘤患者循环肿瘤DNA(ctDNA)的灵敏度和特异度,比较脑脊液与血浆中ctDNA的性能,并分析肿瘤级别对ctDNA检测的影响。Meta分析显示脑脊液ctDNA的AUC为0.947,血浆为0.741,但差异未达统计学显著(P=0.141)。定性分析提示单等位基因PCR和小型靶向下一代测序面板灵敏度更高,高级别胶质瘤ctDNA检测灵敏度高于低级别。

要点

  • 脑脊液ctDNA的AUC为0.947,血浆为0.741,两者差异未达统计学显著(P=0.141)。
  • 单等位基因PCR和小型靶向测序面板的灵敏度高于更广泛的面板。
  • 高级别胶质瘤的ctDNA检测灵敏度高于低级别胶质瘤,但许多研究缺乏特异度报告。

核心结论

  • ctDNA在成人胶质瘤中似乎是一种高灵敏度和高特异度的非侵入性生物标志物。
  • 为最大化其性能,脑脊液应使用靶向遗传分析平台进行研究,尤其是在高级别胶质瘤中。
  • 需要进一步研究ctDNA以明确其在诊断、预后、胶质母细胞瘤假性进展及其他可能考虑新辅助治疗场景中的临床效用。

研究设计与样本

  • 遵循PRISMA指南的系统综述与Meta分析,纳入已发表的评估成人确诊胶质瘤患者血浆或脑脊液中ctDNA的研究。
  • 使用Rücker-Schumacher方法生成汇总受试者工作特征曲线并计算曲线下面积(AUC)。

主要发现

  • Meta分析显示脑脊液ctDNA的AUC为0.947,血浆ctDNA的AUC为0.741,两者差异未达统计学显著(P=0.141)。
  • 定性分析显示单等位基因PCR和小型靶向下一代测序面板的灵敏度高于更广泛的面板。
  • 定性分析显示高级别胶质瘤的ctDNA检测灵敏度高于低级别胶质瘤,但这些分析受限于许多研究缺乏特异度报告。

局限性

  • 脑脊液与血浆ctDNA的AUC差异未达统计学显著(P=0.141)。
  • 关于肿瘤级别对ctDNA检测影响的定性分析受限于许多研究缺乏特异度报告。
  • 需要进一步研究ctDNA以明确其临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker to capture tumor genetics in patients with brain tumors. Research into its clinical utility, however, has not been standardized because the sensitivity and specificity of ctDNA remain undefined. OBJECTIVE: To (1) review the primary literature about ctDNA in adults with glioma to compare the sensitivity and specificity of ctDNA in the cerebrospinal fluid vs the plasma and (2) to evaluate the effect of tumor grade on detection of ctDNA. METHODS: PRISMA-guided systematic review and meta-analysis was performed using published studies that assessed ctDNA in either plasma or cerebrospinal fluid among adult patients with confirmed glioma. Summary receiver operating characteristic curves were generated using the Rücker-Schumacher method, and area under the curve (AUC) was calculated. RESULTS: Meta-analysis revealed improved biomarker performance for CSF (AUC = 0.947) vs plasma (AUC = 0.741) ctDNA, although this did not reach statistical significance ( P = .141). Qualitative analysis revealed greater sensitivities among single-allele PCR and small, targeted next-generation sequencing panels compared with broader panels. It additionally demonstrated higher sensitivity of ctDNA detection in high-grade vs low-grade gliomas, although these analyses were limited by a lack of specificity reporting in many studies. CONCLUSION: ctDNA seems to be a highly sensitive and specific noninvasive biomarker among adults with gliomas. To maximize its performance, CSF should be studied with targeted genetic analysis platforms, particularly in high-grade gliomas. Further studies on ctDNA are needed to define its clinical utility in diagnosis, prognostication, glioblastoma pseudoprogression, and other scenarios wherein neoadjuvant therapies may be considered.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. McMahon JT, Studer M, Ulrich B, et al. Circulating Tumor DNA in Adults With Glioma: A Systematic Review and Meta-Analysis of Biomarker Performance. Neurosurgery. 2022. PMID: 35535984. doi:10.1227/neu.0000000000001982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。